Do women with pre-eclampsia and their babies benifit from management sulphate? The Magpie Trial: a randomised placebo controlled trial

Simple item page
dc.contributor.authorAltman, D.en_US
dc.contributor.authorCarroli, G.en_US
dc.contributor.authorDuley, L.en_US
dc.contributor.authorFarrell, B.en_US
dc.contributor.authorMoodley, J.en_US
dc.contributor.authorNeilson, J.en_US
dc.contributor.authorSmith, D.en_US
dc.contributor.authorFernando, S. with Magpie Trial Collaborative Groupen_US
dc.creator.corporateauthorMagpie Trial Collaborative Groupen_US
dc.date.accessioned2014-10-29T09:19:23Z
dc.date.available2014-10-29T09:19:23Z
dc.date.issued2002en_US
dc.descriptionBACKGROUND: Anticonvulsants are used for pre-eclampsia in the belief they prevent eclamptic convulsions, and so improve outcome. Evidence supported magnesium sulphate as the drug to evaluate. Methods Eligible women (n=10 141) had not given birth or were 24 h or less postpartum; blood pressure of 140/90 mm Hg or more, and proteinuria of 1+ (30 mg/dL) or more; and there was clinical uncertainty about magnesium sulphate. Women were randomised in 33 countries to either magnesium sulphate (n=5071) or placebo (n=5070). Primary outcomes were eclampsia and, for women randomised before delivery, death of the baby. Follow up was until discharge from hospital after delivery. Analyses were by intention to treat.FINDINGS: Follow-up data were available for 10 110 (99•7%) women, 9992 (99%) of whom received the allocated treatment. 1201 of 4999 (24%) women given magnesium sulphate reported side-effects versus 228 of 4993 (5%) given placebo. Women allocated magnesium sulphate had a 58% lower risk of eclampsia (95% CI 40—71) than those allocated placebo (40, 0•8%, vs 96, 1•9%; 11 fewer women with eclampsia per 1000 women). Maternal mortality was also lower among women allocated magnesium sulphate (relative risk 0•55, 0•26—1•14). For women randomised before delivery, there was no clear difference in the risk of the baby dying (576, 12•7%, vs 558, 12•4%; relative risk 1•02, 99% CI 0•92—1•14). The only notable difference in maternal or neonatal morbidity was for placental abruption (relative risk 0•67, 99% CI 0•45—0•89).Interpretation: Magnesium sulphate halves the risk of eclampsia, and probably reduces the risk of maternal death. There do not appear to be substantive harmful effects to mother or baby in the short term.
dc.descriptionIndexed in MEDLINE
dc.identifier.citationLancet. 2002; 359: pp.1877-90en_US
dc.identifier.departmentObstetrics and Gynaecologyen_US
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/1497
dc.publisherLancet Publishing Groupen_US
dc.subjectPre-Eclampsia
dc.subjectPre-Eclampsia-diagnosis
dc.subjectPre-Eclampsia-drug therapy
dc.subjectPre-Eclampsia-prevention and control
dc.subjectPregnancy
dc.subjectFetal Death
dc.subjectAnticonvulsants-therapeutic use
dc.subjectAnticonvulsants-adverse effects
dc.subjectMagnesium Sulfate-adverse effects
dc.subjectMagnesium Sulfate-therapeutic use
dc.subjectRandomized Controlled Trial
dc.subjectClinical Trial
dc.titleDo women with pre-eclampsia and their babies benifit from management sulphate? The Magpie Trial: a randomised placebo controlled trialen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journal/Magazine Articles